State of New Jersey Common Pension Fund D bought a new position in TG Therapeutics, Inc. (NASDAQ:TGTX – Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 113,683 shares of the biopharmaceutical company’s stock, valued at approximately $2,022,000.
Several other hedge funds and other institutional investors have also bought and sold shares of TGTX. Assenagon Asset Management S.A. purchased a new position in shares of TG Therapeutics in the 2nd quarter worth $8,698,000. Eventide Asset Management LLC purchased a new position in TG Therapeutics in the fourth quarter worth about $7,506,000. Bank of New York Mellon Corp grew its stake in shares of TG Therapeutics by 13.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 503,645 shares of the biopharmaceutical company’s stock valued at $8,960,000 after purchasing an additional 59,523 shares during the period. Wellington Management Group LLP increased its position in shares of TG Therapeutics by 1.4% during the 4th quarter. Wellington Management Group LLP now owns 3,139,764 shares of the biopharmaceutical company’s stock valued at $53,627,000 after purchasing an additional 43,290 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its stake in shares of TG Therapeutics by 1.7% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,131,896 shares of the biopharmaceutical company’s stock worth $19,333,000 after purchasing an additional 19,214 shares during the period. Institutional investors own 58.58% of the company’s stock.
TG Therapeutics Stock Down 2.5 %
Shares of TGTX stock opened at $24.65 on Friday. The company has a debt-to-equity ratio of 0.58, a current ratio of 3.58 and a quick ratio of 2.83. TG Therapeutics, Inc. has a one year low of $6.46 and a one year high of $26.41. The company’s fifty day moving average price is $22.01 and its 200-day moving average price is $18.30. The company has a market capitalization of $3.81 billion, a price-to-earnings ratio of 107.17 and a beta of 2.21.
Analyst Upgrades and Downgrades
TGTX has been the subject of a number of research reports. The Goldman Sachs Group upped their target price on shares of TG Therapeutics from $18.00 to $20.00 and gave the company a “neutral” rating in a report on Wednesday, August 7th. HC Wainwright restated a “buy” rating and issued a $49.00 price objective on shares of TG Therapeutics in a research note on Wednesday. Finally, B. Riley lifted their target price on TG Therapeutics from $29.00 to $34.00 and gave the company a “buy” rating in a research report on Wednesday, August 7th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $31.83.
Read Our Latest Report on TGTX
TG Therapeutics Profile
TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.
See Also
- Five stocks we like better than TG Therapeutics
- CD Calculator: Certificate of Deposit Calculator
- Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut
- Industrial Products Stocks Investing
- FedEx Stock Dips: Another Reason to Fear Recession Is Near
- ESG Stocks, What Investors Should Know
- The Half-Penny Revolution: Will SEC’s Reform Benefit Investors?
Want to see what other hedge funds are holding TGTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TG Therapeutics, Inc. (NASDAQ:TGTX – Free Report).
Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.